Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss
Status:
Completed
Trial end date:
2019-12-09
Target enrollment:
Participant gender:
Summary
The goal of the study was to evaluate the safety, tolerability, and the potential ability of
CGF166 delivered through IL-infusion to improve hearing. CGF166 is a recombinant adenovirus 5
(Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1).